DHL Group is significantly expanding its Life Sciences and Healthcare capabilities in Singapore through a series of major infrastructure investments targeting the Asia Pacific market.
The expansion builds on the earlier opening of its Pharma Hub and is designed to strengthen DHL’s Health Logistics network across the region.
The investments include a S$22 million cold-chain hub at Singapore Changi Airport, adding critical capacity for temperature-sensitive pharmaceutical products.
A second DHL Supply Chain Pharma Hub, costing S$7 million, forms part of the broader investment package alongside a new dedicated healthcare handling area within the DHL Express South Asia Hub.
The new facility spans over 8,000 sqm and is designed as a 100% temperature-controlled ambient facility operating at temperatures between 15°C and 25°C with humidity control below 60%.
The site will accommodate approximately 7,680 pallet positions and incorporate GDP-compliant and GMP-aligned infrastructure, including dedicated redressing rooms for pharmaceutical handling.
With both pharma hubs combined, DHL Supply Chain’s total pharmaceutical logistics footprint in Singapore will amount to approximately 16,000 sqm and accommodate around 12,000 pallet positions.
The expanded network is expected to begin operations by the first half of 2027, giving DHL a substantially larger presence in one of Asia’s key logistics corridors.
The investment comes as the Asia Pacific pharmaceutical logistics market is projected to grow from US$163 billion in 2025 to nearly US$239 billion by 2031, reflecting strong underlying demand.
That growth is being driven by rising demand for biologics, vaccines and other temperature-sensitive products that require specialised storage and transportation infrastructure across the region.
Singapore’s position as a major regional hub makes it a natural focal point for pharmaceutical logistics operators looking to serve markets across Southeast Asia and beyond.
The scale of DHL’s commitment underlines how global logistics firms are repositioning themselves to capture a larger share of the fast-growing life sciences supply chain sector.